These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 27053252)

  • 1. Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
    Bortolanza M; Bariotto-Dos-Santos KD; Dos-Santos-Pereira M; da-Silva CA; Del-Bel E
    Neurotox Res; 2016 Jul; 30(1):88-100. PubMed ID: 27053252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease.
    Bortolanza M; Cavalcanti-Kiwiatkoski R; Padovan-Neto FE; da-Silva CA; Mitkovski M; Raisman-Vozari R; Del-Bel E
    Neurobiol Dis; 2015 Jan; 73():377-87. PubMed ID: 25447229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
    Bezard E; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
    Mov Disord; 2013 Jul; 28(8):1088-96. PubMed ID: 23389842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
    Kobylecki C; Hill MP; Crossman AR; Ravenscroft P
    Mov Disord; 2011 Nov; 26(13):2354-63. PubMed ID: 21953539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression.
    Padovan-Neto FE; Ferreira NR; de Oliveira-Tavares D; de Aguiar D; da Silva CA; Raisman-Vozari R; Del Bel E
    Neurosci Lett; 2013 Apr; 541():126-31. PubMed ID: 23428503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
    Cohen SR; Terry ML; Coyle M; Wheelis E; Centner A; Smith S; Glinski J; Lipari N; Budrow C; Manfredsson FP; Bishop C
    Pharmacol Biochem Behav; 2022 Jun; 217():173393. PubMed ID: 35513119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
    Padovan-Neto FE; Echeverry MB; Tumas V; Del-Bel EA
    Neuroscience; 2009 Mar; 159(3):927-35. PubMed ID: 19302833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
    Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
    Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.
    Del-Bel E; Padovan-Neto FE; Szawka RE; da-Silva CA; Raisman-Vozari R; Anselmo-Franci J; Romano-Dutra AC; Guimaraes FS
    Neurotox Res; 2014 Jan; 25(1):33-44. PubMed ID: 23807548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
    Arakawa K; Yuge N; Maehara S
    Pharmacol Rep; 2020 Apr; 72(2):443-448. PubMed ID: 32144743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.
    Ryu YK; Park HY; Go J; Choi DH; Kim YH; Hwang JH; Noh JR; Lee TG; Lee CH; Kim KS
    Mol Neurobiol; 2018 Jul; 55(7):5715-5726. PubMed ID: 29039022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
    Padovan-Neto FE; Cavalcanti-Kiwiatkoviski R; Carolino RO; Anselmo-Franci J; Del Bel E
    Neuropharmacology; 2015 Feb; 89():87-99. PubMed ID: 25196732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
    Hill MP; Ravenscroft P; Bezard E; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
    J Pharmacol Exp Ther; 2004 Jul; 310(1):386-94. PubMed ID: 15004218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ondansetron, a highly selective 5-HT
    Kwan C; Frouni I; Bédard D; Hamadjida A; Huot P
    Eur J Pharmacol; 2020 Mar; 871():172914. PubMed ID: 31926127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
    Murakami Y; Nishijima H; Nakamura T; Furukawa T; Kinoshita I; Kon T; Suzuki C; Tomiyama M
    Neurosci Lett; 2023 May; 806():137248. PubMed ID: 37061023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
    Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists.
    Sebastianutto I; Maslava N; Hopkins CR; Cenci MA
    Neurobiol Dis; 2016 Dec; 96():156-170. PubMed ID: 27597526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.